SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-19-037436
Filing Date
2019-06-25
Accepted
2019-06-25 17:03:22
Documents
6
Period of Report
2019-06-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a19-12089_18k.htm 8-K 39730
2 EX-1.1 a19-12089_1ex1d1.htm EX-1.1 258303
3 EX-5.1 a19-12089_1ex5d1.htm EX-5.1 27757
4 EX-99.1 a19-12089_1ex99d1.htm EX-99.1 15920
5 GRAPHIC g120891kki001.jpg GRAPHIC 2462
6 GRAPHIC g120891mmi001.jpg GRAPHIC 4906
  Complete submission text file 0001104659-19-037436.txt   353407
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 19919247
SIC: 2834 Pharmaceutical Preparations